Integra LifeSciences Holdings (IART) 2009年年度报告「NASDAQ」.pdf

《Integra LifeSciences Holdings (IART) 2009年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Integra LifeSciences Holdings (IART) 2009年年度报告「NASDAQ」.pdf（120页珍藏版）》请在三个皮匠报告上搜索。

1、Medical InstrumentsNeuroSciencesOrthopedics 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009Annual Report 2009Celebrating 20 Years76%14%5%5%Total RevenuesOperating Cash FlowDiluted Earnings Per ShareSelected Financial Data:Company at a GlanCeFo

2、undedin1989andheadquarteredinPlainsboro,NJGrowingshareinspineandextremityreconstructionwithintheorthopedicmarketMarketleadershipinneurosurgeryandmedicalinstrumentsEmploysapproximately3,000worldwideSellsdirectintheU.S.,Canada,majorEuropeanmarketsandAustraliawithdistributorsinover100countries2009 Reve

3、nues by Geographic Area 2009 Revenues Region($in Millions)United States$519.2Europe$93.4Asia Pacific$32.8Other Foreign$37.12009 Revenues by Product Category24%38%38%Product Category%of Total Revenues Key Product Areas 2009 RevenuesOrthopedics 38%MIS spine system,traditional spine fusion,$262 Million

4、 extremity reconstruction,orthobiologics,skin&woundNeuroSciences 38%Dural graft,cranial closure,$257 Million CSF management,ultrasonic aspiration,neuromonitoringMedical Instruments 24%General and specialty hand-held surgical$164 Million instruments in the hospital and office-based,settings surgical

5、headlight To our Stockholders:In 2009,we saw our business diversify and our customer relationships grow as we guided the companyeffectively through a year in which many companies were not so fortunate.We turned challenges intoopportunities.We reduced our debt and focused our acquisition strategy.We

6、invested in infrastructureto prime our business for growth when the economy strengthens.Because of our strategic efforts,we have been able to enter more markets worldwide,introduce newproducts that fulfilled important needs,and increase our bottom-line successfully.With 2009 as a base,the coming yea